相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ritwik Ghosh et al.
CANCER RESEARCH (2011)
Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies
Dana Faratian et al.
CLINICAL CANCER RESEARCH (2011)
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
Gloria Fuentes et al.
BREAST CANCER RESEARCH (2011)
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases
S. J. Aitken et al.
ANNALS OF ONCOLOGY (2010)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer
Karen J. Taylor et al.
BREAST CANCER RESEARCH (2010)
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
Jessica N. McAlpine et al.
BMC CANCER (2009)
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma
F. Vegran et al.
BRITISH JOURNAL OF CANCER (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole
William R. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
The Future of Targeted Therapies in Ovarian Cancer
Susana Banerjee et al.
ONCOLOGIST (2009)
Beyond chemotherapy: targeted therapies in ovarian cancer
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2009)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Cytokines as a key component of cancer-related inflammation
Giovanni Germano et al.
CYTOKINE (2008)
Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients
S. E. Rivkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reversal of drug resistance in ovarian cancer: Where do we go from here?
Stan B. Kaye
JOURNAL OF CLINICAL ONCOLOGY (2008)
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells
Xiao-Feng Le et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation
G. Brockhoff et al.
CELL PROLIFERATION (2007)
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Peter Mullen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer
Alberto Serrano-Olvera et al.
CANCER TREATMENT REVIEWS (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer
KK Zorn et al.
CLINICAL CANCER RESEARCH (2005)
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
RT Marquez et al.
CLINICAL CANCER RESEARCH (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
SK Mohsin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling
XF Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27(Kip1) via multiple signaling pathways
XF Le et al.
CELL CYCLE (2005)
Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer
K Shigemasa et al.
CLINICAL CANCER RESEARCH (2004)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer
F Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The basement membrane matrix in malignancy
JA Engbring et al.
JOURNAL OF PATHOLOGY (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Automated subcellular localization and quantification of protein expression in tissue microarrays
RL Camp et al.
NATURE MEDICINE (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Significance analysis of microarrays applied to the ionizing radiation response
VG Tusher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
